Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile

What is 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile?

CAS No: 763114-25-6

2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile is a compound of defined chemical structure and pharmaceutical significance whose toxicological characterisation supports health-based exposure limit derivation for pharmaceutical manufacturing occupational safety and cross-contamination control. The relationship between molecular structure and biological potency—assessed through structure-activity relationship analysis and experimental pharmacological and toxicological data—determines the OEB classification and the engineering containment requirements governing manufacturing operations involving 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile.

Genotoxicity data for 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile are assessed under the ICH M7 framework for carcinogenic impurity qualification. A positive Ames test result without a clear non-genotoxic mechanism triggers linear extrapolation from carcinogenicity data, with the acceptable intake derived from the TD50 or the

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile is a fluorinated benzonitrile bearing an isobenzofuranone (phthalide) ylidene group. It has been described as a synthetic intermediate in the preparation of the PARP inhibitor olaparib. Understanding its toxicological profile is important for managing occupational exposure and cross-contamination risk during manufacturing.

A PDE or ADE sets a health-based limit on daily exposure to 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Yes, where relevant. The assessment can review available genotoxicity data and structural features that may indicate mutagenic potential. If a concern is identified, ICH M7 principles may be applied to evaluate the risk and to support a suitable limit. Any conclusions and assumptions for 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile are documented so that reviewers can follow the reasoning.

Yes. When a substance has limited human or animal data, a limit can still be derived using read-across from structurally related compounds, structure-based evaluation and the data that do exist. Each assumption made for 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile is documented, and conservative factors are applied where uncertainty remains, so the resulting limit stays scientifically justified.

A PDE, or permitted daily exposure, addresses patient safety by limiting how much of 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile may be carried over into another medicinal product each day. An OEL, or occupational exposure limit, addresses worker safety by limiting airborne concentrations in the workplace. Both draw on the same toxicological evidence but serve different purposes and use different assumptions.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

An assessment should be reviewed when new toxicological or clinical data become available, when the way the substance is used or handled changes, or when relevant regulatory guidance is updated. Periodic review keeps the limits for 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile aligned with current evidence and helps ensure that containment and cleaning decisions remain scientifically justified.

Exposure to 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile can vary between process steps such as charging, transfer, sampling, filtration, drying and equipment cleaning. The assessment considers where airborne or surface contact is most likely, so that the exposure limit can be linked to practical controls such as closed transfer systems, local exhaust ventilation and appropriate personal protective equipment.

The PDE provides a health-based starting point for calculating acceptable residue limits for 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile on shared equipment. These limits can then be compared with results from cleaning studies to show that carryover into the next product stays below a level of concern. Using a scientifically justified PDE makes cleaning acceptance criteria easier to defend.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add 2‐Fluoro‐5‐((3‐Oxoisobenzofuran‐1(3h)‐Ylidene)Methyl)Benzonitrile to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo